Alnylam’s heart drug troubles take center stage at a cardiology conference
AstraZeneca's failed heart drug trial puts the spotlight on Alnylam's cardiovascular treatments at a cardiology conference.
Evidence dossier
Intelligence passport
Measured timeline
- Detected The first matching coverage entered the Archynetys cluster.
- Evidence threshold reached The story had enough independent coverage for an explanatory brief.
- Latest coverage observed Most recent article currently attached to this story cluster.
- Peak measured velocity The recorded velocity reached 5.
Source diversity sample: BioSpace · STAT · News-Medical · Seeking Alpha · Yahoo Finance · Endpoints News.
How this dossier is built: methodology · AI policy · corrections.
The reporting (8)
- ‘Worse than expected’ Wainua data muddies water for TTR silencers BioSpace · 1d ago
- AstraZeneca and Ionis detail surprise failure of heart disease drug, with Alnylam closely watching STAT · 1d ago
- CARDIO-TTRansform trial investigating eplontersen fails to meet primary efficacy endpoint News-Medical · 1d ago
- Alnylam drops as Astra posts trial data for failed heart drug Seeking Alpha · 1d ago
- Is Alnylam (ALNY) Turning Expanded HELIOS-B and Zilebesiran Data Into Durable Cardiovascular Leadership? Yahoo Finance · 1d ago
- Future of AstraZeneca’s gene silencer in heart disease uncertain after trial failure Endpoints News · 1d ago
- In autopsy of failed heart disease study, AstraZeneca raises broader questions about silencer drugs STAT · 1d ago
- Alnylam’s heart drug troubles take center stage at a cardiology conference STAT · 1d ago
Where it stands
AstraZeneca's heart drug trial has failed. The drug, a gene silencer, was intended to treat heart disease. The failure raises questions about the broader category of silencer drugs.
The failure is being discussed at a cardiology conference. Alnylam's own heart drug is under scrutiny. The company is presenting expanded data for its own cardiovascular treatments.
STAT notes that the failure of AstraZeneca's drug could have broader implications for the field of gene silencing in heart disease. The conference is a key venue for discussing the future of cardiovascular treatments.
Synthesized by Archynetys from the headlines below under a strict no-invention contract. ✓ fact-checked: all claims supported by sources Updated 4h ago.
Answered
What drug failed in AstraZeneca's trial?
AstraZeneca's failed drug is a gene silencer intended to treat heart disease.
What is Alnylam presenting at the cardiology conference?
Alnylam is presenting expanded data for its cardiovascular treatments.
What is the significance of the AstraZeneca trial failure?
The failure raises questions about the broader category of silencer drugs and their effectiveness in treating heart disease.
Velocity
How fast coverage is spreading — measured hourly from article rate × source diversity. How this works →
Topics
Related trends
AI can detect heart disease in women using mammograms, study suggests
AI may let routine breast scans flag women's heart disease years before symptoms appear.
Calcium heart scans sharpen risk estimates mainly for borderline-risk adults
A $100 heart scan could reveal hidden heart disease before symptoms appear, but who benefits?
Shingles vaccine linked to 24% lower dementia risk
A single vaccine shows a 24% dip in dementia risk, reshaping hopes for aging populations
This Habit Could Lower Your Risk of Heart-Related Death by 39%, Study Says
Choosing stairs over elevators may slash heart‑death risk by 39%, sparking a wave of health‑focused lifestyle advice.
Meet VO2 maxxing: The fitness ‘trend’ that could help you live longer
A new fitness trend promises longer life, but the science is not settled
5 Heart-Healthy Habits Doctors Wish More People Started Sooner
A cardiologist's 8,000 surgeries inform new advice on heart health habits
Open prediction lab
Can you beat the machine?
Pick tomorrow's top trend, then compare your result with Archynetys's self-graded forecast.
📬 The daily trend digest
The world's top trends, once a day. No spam, one-click unsubscribe.